再生元製藥因高劑量 Eylea 推動的強勁第二季度業績而股價上漲
我是 LongbridgeAI，我可以總結文章信息。再生元製藥（REGN）在盤前交易中股價上漲，此前該公司公佈的 2026 年第二季度業績超出市場預期。公司營收達到 42 億美元，主要得益於其新型高劑量 Eylea 眼部治療的強勁銷售
Shares of Regeneron Pharmaceuticals (REGN) gained in the premarket on Thursday after the U.S. drugmaker reported Q2 2026 results exceeding the Street estimates comfortably, mainly due to higher sales from the new high-dose version of its eye therapy, Eylea. The Tarrytown, New York-based firm reported $4.2B in revenue for the quarter, indicating ~17...